+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Plasma Fractionation Market by Product [IVIG, Albumin, Factor VIII, von Willebrand Factor, PCC, Protease Inhibitor], Application, End User - Global Forecast to 2024

  • ID: 4760748
  • Report
  • Region: Global
  • 301 Pages
  • Markets and Markets
1 of 6
The Global Plasma Fractionation Market is Projected to Reach USD 34.9 Billion by 2024 from USD 25.4 Billion in 2019, at a CAGR of 6.6%

FEATURED COMPANIES

  • Biotest
  • China Biologic Products
  • CSL
  • Grifols
  • Kedrion
  • LFB
  • MORE

Global plasma fractionation market is projected to grow at a CAGR of 6.6%.

Growth in the plasma fractionation market can largely be attributed to factors such as the growing use of immunoglobulins in various therapeutic areas, increase in plasma collection (and the number of plasma collection centers), and the increasing use of alpha-1-antitrypsin. However, the high cost of plasma products, limited reimbursements, and the emergence of recombinant alternatives are expected to restrain the growth of this market during the forecast period.

By product, immunoglobulin market is expected to hold the largest share of the plasma fractionation market in 2019.

The immunoglobulin segment is expected to dominate the plasma fractionation market during the forecast period. IVIg is the most extensively used plasma product across the globe, meant for the treatment of dermatomyositis, Guillain-Barre syndrome, chronic inflammatory demyelinating polyneuropathy (CIDP), immune cytopenias, hypogammaglobinemia, primary antibody deficiency, vacuities, multiple sclerosis, asthma, and systemic lupus erythematosus, among other ailments. The growing prevalence of these and other target diseases, as a result, is the key driver of market growth.

Factor VIII will dominate the coagulation factor concentrates market in 2019.

The coagulation factor market is segmented into factor VIII, factor IX, Von Willebrand factor, prothrombin factor concentrates, fibrinogen concentrates, and factor XIII. Factor VIII segment is expected to hold the largest share in the coagulation factor concentrates market in 2019. This is attributed to the growth in geriatric population, rising number of hemophilic patients, increasing preference for prophylactic treatments for people suffering from hemophilia, and increasing diagnosis of hemophilia. In addition, the unavailability of advanced therapies for a majority of hemophilia patients in developing countries is also expected to drive this market. 

North America is expected to hold the largest share during the forecast period (2019–2024)

North America is expected to dominate the plasma fractionation market during the forecast period. The demand for plasma products in North America is mainly driven by the increasing use of immunoglobulins in neurological and autoimmune diseases and the increasing use of prophylaxis treatments among diagnosed patients. The rising number of registered hemophilic patients (as illustrated in the table below) is also propelling the growth of this market. The growing number of hemophilic patients will increase the adoption of coagulation factors, which in turn will drive the market for plasma fractionation in North America.

A breakdown of supply-side primary participants is mentioned below:

  • By Company Type: Tier 1–38%, Tier 2–21%, and Tier 3–41%
  • By Designation: C-level–30%, Director Level–28%, Others–42%
  • By Region: North America–35%, Europe–25%, Asia Pacific–20%, Latin America–12%, Middle East and Africa-8%

Major players in the global plasma fractionation market include CSL (Australia), Grifols (Spain), Shire (Ireland), Octapharma (Switzerland), Kedrion (Italy), BPL (UK), Sanquin (Netherlands), LFB (France), Biotest (Germany), Japan Blood Products Organization, China Biologic Products (China), Green Cross Corporation (South Korea), and Shanghai RAAS Blood Products (China).

Research Coverage:

The plasma fractionation market in this report is segmented by product, application, end user, and region. It provides detailed information regarding the major factors influencing the growth market (drivers, restraints, opportunities, and industry-specific challenges). The study tracks and analyzes competitive developments (such as partnerships, agreements, collaborations, mergers & acquisitions, product developments, geographical expansions, and R&D activities) and strategically profiles the key players and comprehensively analyzes their market shares and core competencies in the plasma fractionation market.

Reasons to buy this report:

From an insight perspective, this research report has focused on various levels of analysis—the market share analysis of top players in the global market, different product segments, as well on the regional levels, company profiles that comprise and discuss basic views on the competitive landscape; emerging and high-growth segments of the plasma fractionation market; high-growth regions; and market drivers, restraints, and opportunities.

The report provides the latest statistics and industry trends, allowing buyers to identify high-growth product segments and potential customers and suppliers, hence driving revenue growth and profitability. The report provides insights on the following pointers:

  • Market Penetration: Comprehensive information on products offered by the top players in the global plasma fractionation market
  • Product Development/Innovation: Detailed insights on growth strategies, research & development activities, and product launches in the global plasma fractionation market
  • Market Development: Comprehensive information about lucrative emerging markets–the report analyzes the markets for plasma fractionation across regions
  • Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the global plasma fractionation market
  • Competitive Assessment: In-depth assessment of market shares, strategies, products, and manufacturing capabilities of the leading players in the global plasma fractionation market
Note: Product cover images may vary from those shown
2 of 6

FEATURED COMPANIES

  • Biotest
  • China Biologic Products
  • CSL
  • Grifols
  • Kedrion
  • LFB
  • MORE

1 Introduction
1.1 Objectives of the Study
1.2 Market Definition
1.3 Scope of the Study
1.3.1 Markets Covered
1.3.2 Years Considered for the Study
1.4 Currency
1.5 Stakeholders

2 Research Methodology
2.1 Research Approach
2.1.1 Secondary Sources
2.1.1.1 Key Data From Secondary Sources
2.1.2 Primary Sources
2.1.2.1 Primary Sources
2.1.2.2 Key Data From Primary Sources
2.1.2.3 Key Industry Insights
2.2 Market Size Estimation
2.2.1 Bottom-Up Approach
2.2.2 Top-Down Approach
2.3 Market Breakdown and Data Triangulation
2.4 Market Share Estimation
2.5 Assumptions for the Study
2.6 Limitations

3 Executive Summary

4 Premium Insights
4.1 Plasma Fractionation Market Overview
4.2 Geographical Snapshot of the Plasma Fractionation Market
4.3 Plasma Fractionation Market: Regional Mix
4.4 Plasma Fractionation Market, Developing Countries vs Developed Countries

5 Market Overview
5.1 Introduction
5.2 Market Dynamics
5.2.1 Market Drivers
5.2.1.1 Growing Use of Immunoglobulins in Various Therapeutic Areas
5.2.1.2 Rising Geriatric Population Across the Globe
5.2.1.3 Growing Prevalence of Respiratory Diseases and Aatd Driving the Uptake of Alpha-1-Antitrypsin
5.2.1.4 Increase in Plasma Collection
5.2.2 Market Restraints
5.2.2.1 High Cost and Limited Reimbursement
5.2.2.2 Emergence of Recombinant Alternatives
5.2.3 Market Opportunities
5.2.3.1 Rising Prevalence of Bleeding Disorders
5.2.4 Market Challenges
5.2.4.1 Stringent Government Regulations

6 Industry Insights
6.1 Introduction
6.2 Key Industry Trends
6.2.1 Focus on Increasing Fractionation Capacities
6.2.2 New Indications for Plasma Products
6.2.3 Rising Adoption of SCIg
6.2.4 Increasing Number of Fractionator-Owned Plasma Collection Centers
6.2.5 Growing Plasma Products Market in China
6.2.6 Increasing Focus of Plasma Fractionators Towards Manufacturing and Developing Recombinant Factors
6.3 Porter’s Five Forces
6.3.1 Threat of New Entrants
6.3.2 Threat of Substitutes
6.3.3 Bargaining Power of Suppliers
6.3.4 Bargaining Power of Buyers
6.3.5 Intensity of Competitive Rivalry
6.4 Vendor Benchmarking
6.4.1 Product Portfolio Analysis: Plasma Fractionation Market
6.4.2 No. of Plasma Collection Centers and Fractionation Capacities, By Key Player
6.4.3 Business Presence of Key Players in the Value Chain
6.5 Pricing Analysis

7 Plasma Fractionation Market, By Product
7.1 Introduction
7.2 Immunoglobulins
7.2.1 Intravenous Immunoglobulins
7.2.1.1 IVIg Holds the Largest Share of the Immunoglobulins Market
7.2.2 Subcutaneous Immunoglobulins
7.2.2.1 Benefit of Self-Administration and Lower Incidence of Non-Serious Systemic Adverse Reactions Will Drive the Growth of the SCIg Market
7.2.3 Other Immunoglobulins
7.3 Coagulation Factor Concentrates
7.3.1 Factor VIII
7.3.1.1 Factor VIII Holds the Largest Share of the Coagulation Factor Concentrates Market
7.3.2 Factor IX
7.3.2.1 Growth in the Aging Population and the Rise in the Number of Hemophilic Patients is Expected to Drive the Growth in This Market
7.3.3 Von Willebrand Factor
7.3.3.1 Market Growth is Primarily Driven By the Increasing Prevalence and Diagnosis of Von Willebrand Disease and Hemophilia
7.3.4 Prothrombin Complex Concentrate
7.3.4.1 Advantages of Pcc Over Fresh Frozen Plasma Will Support Market Growth in This Segment
7.3.5 Fibrinogen Concentrates
7.3.5.1 Safety Profile, Accuracy, and Speed of Administration Have Supported the Growth of the Fibrinogen Concentrates Market
7.3.6 Factor XIII
7.3.6.1 Applications in Treating Rare Bleeding Disorders Will Contribute to the Demand for Factor XIII
7.4 Albumin
7.4.1 Wide Demand for Albumin as an Antioxidant and Volume Expander Will Drive Market Growth
7.5 Protease Inhibitors
7.5.1 Increasing Global Disease Burden Will Drive Demand for Protease Inhibitors
7.6 Other Products

8 Plasma Fractionation Market, By Application
8.1 Introduction
8.2 Neurology
8.2.1 Rising Prevalence of Major Age-Related Neurological Disorders to Drive This Market
8.3 Immunology
8.3.1 Increasing Prevalence of Immunodeficiency Disorders Among Children and Adults to Drive the Growth of This Market
8.4 Hematology
8.4.1 Growth in the Number of Hemophilia Patients to Drive the Demand for Coagulation Factor Concentrates and Immunoglobulins
8.5 Critical Care
8.5.1 Increasing Off-Label Use of Albumin and Rising Use of Anticoagulants to Drive the Demand for Plasma-Derived Critical Care Products
8.6 Pulmonology
8.6.1 Rising Prevalence of Alpha-1 Antitrypsin Deficiency and Copd to Drive the Plasma Fractionation Market for Pulmonology
8.7 Hemato-Oncology
8.7.1 Rising Number of Blood Cancer Patients to Drive the Demand for Plasma-Derived Products in Hemato-Oncology
8.8 Rheumatology
8.8.1 Increasing Prevalence of Rheumatic Conditions to Drive the Plasma Fractionation Market for Rheumatology
8.9 Other Applications

9 Plasma Fractionation Market, By End User
9.1 Introduction
9.2 Hospitals & Clinics
9.2.1 Improving Healthcare Infrastructure and Growth in the Number of Hospitals & Clinics—Key Factors Driving Growth
9.3 Clinical Research Laboratories
9.3.1 Increasing Number of Clinical Studies on New Therapeutic Indications for Plasma-Derived Products to Drive the Market for Clinical Research Laboratories
9.4 Academic Institutes
9.4.1 Increasing Basic Medical Research Activities and Growing Demand for New Drug Molecules to Drive the Demand for Plasma Products in Academic Institutes

10 Plasma Fractionation Market, By Region
10.1 Introduction
10.2 North America
10.2.1 US
10.2.1.1 The US Dominates the Global Plasma Fractionation Market
10.2.2 Canada
10.2.2.1 Canada is One of the World's Highest Per Capita Users of IVIg
10.3 Europe
10.3.1 Germany
10.3.1.1 Germany has the Highest Plasma Fractionation Capacity in Europe
10.3.2 France
10.3.2.1 High Prevalence of Bleeding Disorders to Drive the Market for Plasma Fractionation in France
10.3.3 Italy
10.3.3.1 Growth in the Country’s Geriatric Population to Drive the Market for Plasma Fractionation
10.3.4 Spain
10.3.4.1 Growing Demand for Plasma Products for the Treatment of Chronic Diseases in the Elderly is the Key Factor Driving Market Growth
10.3.5 UK
10.3.5.1 Increasing Incidence of Hemophilia and the Growing Consumption of Coagulation Factors to Drive Market Growth in the UK
10.3.6 Rest of Europe
10.4 Asia Pacific
10.4.1 China
10.4.1.1 Significant Growth in the Incidence of Diseases Such as Hypoalbuminemia, Liver Cancer, and Hepatitis B are Driving the Growth of Plasma-Derived Products Market in China
10.4.2 Japan
10.4.2.1 The Rising Geriatric Population is Expected to Increase the Prevalence of Neurological Disorders and Hematological Diseases in Japan in the Coming Years
10.4.3 Australia
10.4.3.1 High Production of Plasma Products and the Growing Demand for Plasma Products for the Treatment of Chronic Disease to Drive Market Growth
10.4.4 India
10.4.4.1 Growing Healthcare Awareness, Availability of Better Diagnostic Tools, and the Rising Geriatric Population to Drive Market Growth
10.4.5 Vietnam
10.4.5.1 Growing Pool of Patients Suffering From Copd, Pid, and Bleeding Disorders to Drive Market Growth
10.4.6 Indonesia
10.4.6.1 Growing Government Initiatives to Drive Market Growth
10.4.7 Malaysia
10.4.7.1 Growing Healthcare Awareness, Increasing Prevalence of Bleeding Disorders, and the Rising Geriatric Population are the Major Factors Driving Market Growth
10.4.8 Rest of Asia Pacific
10.5 Latin America
10.5.1 Implementation of Government Initiatives to Promote Healthcare Services, Rising Geriatric Population, and Increasing Incidence of Bleeding Disorders to Drive Market Growth in Latin America
10.6 Middle East & Africa
10.6.1 Turkey
10.6.1.1 Turkey Dominated the Plasma Fractionation Market in the Middle East and Africa
10.6.2 Saudi Arabia
10.6.2.1 Rising Use of Immunoglobulins in Neurology and Immunology and the Strengthening of Healthcare Infrastructure to Drive Market Growth
10.6.3 Egypt
10.6.3.1 Growing Research on Plasma and Plasma Derivatives and the Increasing Adoption of Plasma Products to Drive Market Growth
10.6.4 UAE
10.6.4.1 Increasing Incidence of Bleeding Disorders and Growing Government Initiatives for Healthcare Infrastructure Development to Drive Market Growth
10.6.5 Rest of Middle East and Africa

11 Competitive Landscape
11.1 Overview
11.2 Market Share Analysis
11.2.1 Market Share Analysis, By Product,2018
11.2.1.1 Immunoglobulin Market, By Key Players
11.2.1.1.1 IVIg Market, By Key Players
11.2.1.2 Coagulation Factor Market, By Key Players
11.2.1.2.1 Factor VIII Market, By Key Players
11.2.1.3 Albumin Market, By Key Players
11.2.2 Market Share Analysis, By Region,2018
11.2.2.1 North America Plasma Fractionation Market, By Key Players
11.2.2.1.1 US Plasma Fractionation Market, By Key Players
11.2.2.2 Europe Plasma Fractionation Market, By Key Players
11.3 Competitive Leadership Mapping
11.3.1 Visionary Leaders
11.3.2 Innovators
11.3.3 Dynamic Differentiators
11.3.4 Emerging Companies
11.4 Competitive Scenario and Trends
11.4.1 Product Launches/Approvals
11.4.2 Expansions
11.4.3 Acquisitions
11.4.4 Agreements, Collaborations, Joint Ventures, and Partnerships

12 Company Profiles
12.1 CSL
12.1.1 Business Overview
12.1.2 Products Offered
12.1.3 Recent Developments
12.1.4 SWOT Analysis
12.1.5 MnM View
12.2 Grifols
12.2.1 Business Overview
12.2.2 Products Offered
12.2.3 Recent Developments
12.2.4 SWOT Analysis
12.2.5 MnM View
12.3 Shire
12.3.1 Business Overview
12.3.2 Products Offered
12.3.3 Recent Developments
12.3.4 SWOT Analysis
12.3.5 MnM View
12.4 Octapharma
12.4.1 Business Overview
12.4.2 Products Offered
12.4.3 Recent Developments
12.4.4 SWOT Analysis
12.4.5 MnM Analysis
12.5 Kedrion
12.5.1 Business Overview
12.5.2 Products Offered
12.5.3 Recent Developments
12.5.4 SWOT Analysis
12.5.5 MnM View
12.6 LFB
12.6.1 Business Overview
12.6.2 Products Offered
12.6.3 Recent Developments
12.6.4 MnM View
12.7 Biotest
12.7.1 Business Overview
12.7.2 Products Offered
12.7.3 Recent Developments
12.7.4 MnM View
12.8 Sanquin
12.8.1 Business Overview
12.8.2 Products Offered
12.8.3 MnM View
12.9 China Biologic Products
12.9.1 Business Overview
12.9.2 Products Offered
12.9.3 Recent Developments
12.9.4 MnM View
12.10 Bio Products Laboratory (BPL)
12.10.1 Business Overview
12.10.2 Products Offered
12.10.3 Recent Developments
12.10.4 MnM View
12.11 Japan Blood Products Organization
12.11.1 Business Overview
12.11.2 Products Offered
12.11.3 MnM View
12.12 GC Pharma (Green Cross Corporation)
12.12.1 Business Overview
12.12.2 Products Offered
12.12.3 Recent Developments
12.12.4 MnM View
12.13 Shanghai RAAS Blood Products
12.13.1 Business Overview
12.13.2 Products Offered
12.13.3 Recent Developments
12.13.4 MnM View

13 Appendix
13.1 Insights of Industry Experts
13.2 Discussion Guide
13.3 Available Customization
13.4 Knowledge Store: Subscription Portal
13.5 Related Report
13.6 Author Details

List of Tables (265 Tables)
Table 1 Plasma Fractionation Market: Impact Analysis
Table 2 On-Label and Off-Label Indications of IVIG
Table 3 Number of Clinical Studies on Immunoglobulins, By Region, 2017
Table 4 Number of Patients Treated for Top 10 Target Conditions in the UK (2015-16)
Table 5 Increase in Geriatric Population From 2000 to 2050 Across the Globe
Table 6 Number of Plasma Collection Centers, By Company, 2018
Table 7 Number of Hemophilia Patients in Developed and Emerging Countries, 2016 vs 2017
Table 8 Fractionation Capacity Expansions By Major Players
Table 9 Per Capita Consumption of IVIG and Albumin, By Country (2014)
Table 10 China: Top Players in the Plasma Fractionation Market, 2018
Table 11 Major Local Players in China
Table 12 Regional Impact Analysis of Recombinant Factors on Plasma-Derived Products
Table 13 Average Selling Price of Plasma Fractionation Products, By Player (2018)
Table 14 Average Selling Price of Plasma Fractionation Products, By Region (2018)
Table 15 Plasma Fractionation Market, By Product, 2017–2024 (USD Million)
Table 16 IVIG vs SCIG Therapy
Table 17 Immunoglobulins Market, By Type, 2017–2024 (USD Million)
Table 18 Immunoglobulins Market, By Country, 2017–2024 (USD Million)
Table 19 Intravenous Immunoglobulins Offered By Key Market Players
Table 20 Intravenous Immunoglobulins Market, By Country, 2017–2024 (USD Million)
Table 21 Intravenous Immunoglobulins Market, By Region, 2017–2024 (Metric Tons)
Table 22 Subcutaneous Immunoglobulins Offered By Key Market Players
Table 23 Subcutaneous Immunoglobulins Market, By Country, 2017–2024 (USD Million)
Table 24 Subcutaneous Immunoglobulins Market, By Region, 2017–2024 (Metric Tons)
Table 25 Other Immunoglobulins Offered By Key Market Players
Table 26 Other Immunoglobulins Market, By Country, 2017–2024 (USD Million)
Table 27 Other Immunoglobulins Market, By Region, 2017–2024 (Million International Units)
Table 28 Coagulation Factor Concentrates Market, By Type, 2017–2024 (USD Million)
Table 29 Coagulation Factor Concentrates Market, By Country, 2017–2024 (USD Million)
Table 30 Factor VIII Offered By Key Market Players
Table 31 Factor VIII Market, By Country, 2017–2024 (USD Million)
Table 32 Factor VIII Market, By Region, 2017–2024 (Million International Units)
Table 33 Factor IX Offered By Key Market Players
Table 34 Factor IX Market, By Country, 2017–2024 (USD Million)
Table 35 Von Willebrand Factor Offered By Key Market Players
Table 36 Von Willebrand Factor Market, By Country, 2017–2024 (USD Million)
Table 37 Prothrombin Complex Concentrates Offered By Key Market Players
Table 38 Prothrombin Complex Concentrates Market, By Country, 2017–2024 (USD Million)
Table 39 Fibrinogen Concentrates Offered By Key Market Players
Table 40 Fibrinogen Concentrates Market, By Country, 2017–2024 (USD Million)
Table 41 Factor XIII Offered By Key Market Players
Table 42 Factor XIII Market, By Country, 2017–2024 (USD Million)
Table 43 Albumin Offered By Key Market Players
Table 44 Albumin Market, By Country, 2017–2024 (USD Million)
Table 45 Global Albumin Market, By Region, 2017–2024 (Metric Tons)
Table 46 Protease Inhibitors Offered By Key Market Players
Table 47 Protease Inhibitors Market, By Country, 2017–2024 (USD Million)
Table 48 Other Products Market, By Country, 2017–2024 (USD Million)
Table 49 Plasma Fractionation Market, By Application, 2017–2024 (USD Million)
Table 50 Number of Dalys for Neurological Disorders and the Percentage of Dalys Projected for 2005, 2015, and 2030
Table 51 Plasma-Derived Products and Their Applications in Neurology
Table 52 Plasma Fractionation Market for Neurology, By Country, 2017–2024 (USD Million)
Table 53 List of Fda-Approved Indications for Immunoglobulins in Immunology
Table 54 Primary Immunodeficiency Disease, By Type
Table 55 Prevalence of Primary Immunodeficiency Disease, By Region, 2013 vs 2015
Table 56 Plasma-Derived Products and Their Applications in Immunology
Table 57 Plasma Fractionation Market for Immunology, By Country, 2017–2024 (USD Million)
Table 58 Number of Hemophilia Patients (2012–2017)
Table 59 Plasma-Derived Products and Their Applications in Hematology
Table 60 Plasma Fractionation Market for Hematology, By Country, 2017–2024 (USD Million)
Table 61 Plasma-Derived Products and Their Applications in Critical Care
Table 62 Plasma Fractionation Market for Critical Care, By Country, 2017–2024 (USD Million)
Table 63 Plasma-Derived Products and Their Applications in Pulmonology
Table 64 Plasma Fractionation Market for Pulmonology, By Country, 2017–2024 (USD Million)
Table 65 Incidence of Leukemia, Multiple Myeloma, and Hodgkin Lymphoma, By Region, 2012 vs 2015 vs 2018
Table 66 Plasma-Derived Products and Their Applications in Hemato-Oncology
Table 67 Plasma Fractionation Market for Hemato-Oncology, By Country, 2017–2024 (USD Million)
Table 68 Plasma Fractionation Market for Rheumatology, By Country, 2017–2024 (USD Million)
Table 69 Plasma-Derived Products for Other Applications
Table 70 Plasma Fractionation Market for Other Applications, By Country, 2017–2024 (USD Million)
Table 71 Plasma Fractionation Market, By End USer, 2017–2024 (USD Million)
Table 72 Plasma Fractionation Market for Hospitals & Clinics, By Country, 2017–2024 (USD Million)
Table 73 Clinical Studies on Albumin & Immunoglobulin (2017)
Table 74 Plasma Fractionation Market for Clinical Research Laboratories, By Country, 2017–2024 (USD Million)
Table 75 Plasma Fractionation Market for Academic Institutes, By Country, 2017–2024 (USD Million)
Table 76 Regional Distribution of Plasma Fractionation Plants and Plasma Throughput, By Region, 2014
Table 77 Plasma Fractionation Market, By Region, 2017–2024 (USD Million)
Table 78 North America: Hemophilia Patients, 2013 vs 2017
Table 79 Transfer of Plasma From US to Other Regions, 2014
Table 80 North America: Plasma Fractionation Market, By Country, 2017–2024 (USD Million)
Table 81 North America: Plasma Fractionation Market, By Product, 2017–2024 (USD Million)
Table 82 North America: Immunoglobulins Market, By Type, 2017–2024 (USD Million)
Table 83 North America: Coagulation Factor Concentrates Market, By Type, 2017–2024 (USD Million)
Table 84 North America: Plasma Fractionation Market, By Application, 2017–2024 (USD Million)
Table 85 North America: Plasma Fractionation Market, By End User, 2017–2024 (USD Million)
Table 86 US: Key Macroindicators for the Plasma Fractionation Market
Table 87 US: Plasma Fractionation Market, By Product, 2017–2024 (USD Million)
Table 88 US: Immunoglobulins Market, By Type, 2017–2024 (USD Million)
Table 89 US: Coagulation Factor Concentrates Market, By Type, 2017–2024 (USD Million)
Table 90 US: Plasma Fractionation Market, By Application, 2017–2024 (USD Million)
Table 91 US: Plasma Fractionation Market, By End User, 2017–2024 (USD Million)
Table 92 Canada: Key Macroindicators for the Plasma Fractionation Market
Table 93 Canada: Plasma Fractionation Market, By Product, 2017–2024 (USD Million)
Table 94 Canada: Immunoglobulins Market, By Type, 2017–2024 (USD Million)
Table 95 Canada: Coagulation Factor Concentrates Market, By Type, 2017–2024 (USD Million)
Table 96 Canada: Plasma Fractionation Market, By Application, 2017–2024 (USD Million)
Table 97 Canada: Plasma Fractionation Market, By End User, 2017–2024 (USD Million)
Table 98 Europe: Plasma Collection, 2007–2016
Table 99 Plasma Fractionation Plants in Europe (2017)
Table 100 Europe: Plasma Fractionation Market, By Country, 2017–2024 (USD Million)
Table 101 Europe: Plasma Fractionation Market, By Product, 2017–2024 (USD Million)
Table 102 Europe: Immunoglobulins Market, By Type, 2017–2024 (USD Million)
Table 103 Europe: Coagulation Factor Concentrates Market, By Type, 2017–2024 (USD Million)
Table 104 Europe: Plasma Fractionation Market, By Application, 2017–2024 (USD Million)
Table 105 Europe: Plasma Fractionation Market, By End User, 2017–2024 (USD Million)
Table 106 Germany: Key Macroindicators for the Plasma Fractionation Market
Table 107 Germany: Plasma Fractionation Market, By Product, 2017–2024 (USD Million)
Table 108 Germany: Immunoglobulins Market, By Type, 2017–2024 (USD Million)
Table 109 Germany: Coagulation Factor Concentrates Market, By Type, 2017–2024 (USD Million)
Table 110 Germany: Plasma Fractionation Market, By Application, 2017–2024 (USD Million)
Table 111 Germany: Plasma Fractionation Market, By End User, 2017–2024 (USD Million)
Table 112 Number of People With Bleeding Disorders in France, 2012–2017
Table 113 France: Key Macroindicators for the Plasma Fractionation Market
Table 114 France: Plasma Fractionation Market, By Product, 2017–2024 (USD Million)
Table 115 France: Immunoglobulins Market, By Type, 2017–2024 (USD Million)
Table 116 France: Coagulation Factor Concentrates Market, By Type, 2017–2024 (USD Million)
Table 117 France: Plasma Fractionation Market, By Application, 2017–2024 (USD Million)
Table 118 France: Plasma Fractionation Market, By End User, 2017–2024 (USD Million)
Table 119 Italy: Number of Blood Donations, 2011 vs 2013
Table 120 Production of Plasma Products in Italy (2013, 2018-E, & 2023-E)
Table 121 Italy: Key Macroindicators for the Plasma Fractionation Market
Table 122 Italy: Plasma Fractionation Market, By Product, 2017–2024 (USD Million)
Table 123 Italy: Immunoglobulins Market, By Type, 2017–2024 (USD Million)
Table 124 Italy: Coagulation Factor Concentrates Market, By Type, 2017–2024 (USD Million)
Table 125 Italy: Plasma Fractionation Market, By Application, 2017–2024 (USD Million)
Table 126 Italy: Plasma Fractionation Market, By End User, 2017–2024 (USD Million)
Table 127 Spain: Key Macroindicators for the Plasms Fractionation Market
Table 128 Spain: Plasma Fractionation Market, By Product, 2017–2024 (USD Million)
Table 129 Spain: Immunoglobulins Market, By Type, 2017–2024 (USD Million)
Table 130 Spain: Coagulation Factor Concentrates Market, By Type, 2017–2024 (USD Million)
Table 131 Spain: Plasma Fractionation Market, By Application, 2017–2024 (USD Million)
Table 132 Spain: Plasma Fractionation Market, By End User, 2017–2024 (USD Million)
Table 133 Usage of Immunoglobulins
Table 134 Estimated Number of Hemophilia A and Hemophilia B Patients in the Uk, 2012–2016
Table 135 Volume of Immunoglobulins Used for the Top 5 Diagnoses (2016)
Table 136 UK: Key Macroindicators for the Plasma Fractionation Market
Table 137 UK: Plasma Fractionation Market, By Product, 2017–2024 (USD Million)
Table 138 UK: Immunoglobulins Market, By Type, 2017–2024 (USD Million)
Table 139 UK: Coagulation Factor Concentrates Market, By Type, 2017–2024 (USD Million)
Table 140 UK: Plasma Fractionation Market, By Application, 2017–2024 (USD Million)
Table 141 UK: Plasma Fractionation Market, By End User, 2017–2024 (USD Million)
Table 142 Total Number of Hemophilia Patients in Rest of Europe: 2012–2017
Table 143 RoE: Plasma Fractionation Market, By Product, 2017–2024 (USD Million)
Table 144 RoE: Immunoglobulins Market, By Type, 2017–2024 (USD Million)
Table 145 RoE: Coagulation Factor Concentrates Market, By Type, 2017–2024 (USD Million)
Table 146 RoE: Plasma Fractionation Market, By Application, 2017–2024 (USD Million)
Table 147 RoE: Plasma Fractionation Market, By End User, 2017–2024 (USD Million)
Table 148 Asia Pacific: Plasma Fractionation Market, By Country, 2017–2024 (USD Million)
Table 149 Asia Pacific: Plasma Fractionation Market, By Product, 2017–2024 (USD Million)
Table 150 Asia Pacific: Immunoglobulins Market, By Type, 2017–2024 (USD Million)
Table 151 Asia Pacific: Coagulation Factor Concentrates Market, By Type, 2017–2024 (USD Million)
Table 152 Asia Pacific: Plasma Fractionation Market, By Application, 2017–2024 (USD Million)
Table 153 Asia Pacific: Plasma Fractionation Market, By End User, 2017–2024 (USD Million)
Table 154 China: Key Macroindicators for the Plasma Fractionation Market
Table 155 China: Plasma Fractionation Market, By Product, 2017–2024 (USD Million)
Table 156 China: Immunoglobulins Market, By Type, 2017–2024 (USD Million)
Table 157 China: Coagulation Factor Concentrates Market, By Type, 2017–2024 (USD Million)
Table 158 China: Plasma Fractionation Market, By Application, 2017–2024 (USD Million)
Table 159 China: Plasma Fractionation Market, By End User, 2017–2024 (USD Million)
Table 160 Mean Per Capita Factor VIII and IX Use in Japan, 2014 vs 2017 (In Iu/Total Population)
Table 161 Patients With Bleeding Disorders in Japan, 2014 vs 2017
Table 162 Japan: Key Macroindicators for the Plasma Fractionation Market
Table 163 Japan: Plasma Fractionation Market, By Product, 2017–2024 (USD Million)
Table 164 Japan: Immunoglobulins Market, By Type, 2017–2024 (USD Million)
Table 165 Japan: Coagulation Factor Concentrates Market, By Type, 2017–2024 (USD Million)
Table 166 Japan: Plasma Fractionation Market, By Application, 2017–2024 (USD Million)
Table 167 Japan: Plasma Fractionation Market, By End User, 2017–2024 (USD Million)
Table 168 Total Ig (Grams) Used in Australia, 2006–2015
Table 169 Australian Government Funding for the Supply of Blood and Blood Products, 2008–2017 (USD Million)
Table 170 Australia: Blood Sector Overview (2017)
Table 171 Australia: Key Macroindicators for the Plasma Fractionation Market
Table 172 Australia: Plasma Fractionation Market, By Product, 2017–2024 (USD Million)
Table 173 Australia: Immunoglobulins Market, By Type, 2017–2024 (USD Million)
Table 174 Australia: Coagulation Factor Concentrates Market, By Type, 2017–2024 (USD Million)
Table 175 Australia: Plasma Fractionation Market, By Application, 2017–2024 (USD Million)
Table 176 Australia: Plasma Fractionation Market, By End User, 2017–2024 (USD Million)
Table 177 India: Number of Patients With Bleeding Disorders, 2012–2016
Table 178 India: Key Macroindicators for the Plasma Fractionation Market
Table 179 India: Plasma Fractionation Market, By Product, 2017–2024 (USD Million)
Table 180 India: Immunoglobulins Market, By Type, 2017–2024 (USD Million)
Table 181 India: Coagulation Factor Concentrates Market, By Type, 2017–2024 (USD Million)
Table 182 India: Plasma Fractionation Market, By Application, 2017–2024 (USD Million)
Table 183 India: Plasma Fractionation Market, By End User, 2017–2024 (USD Million)
Table 184 Vietnam: Key Macroindicators for the Plasma Fractionation Market
Table 185 Vietnam: Plasma Fractionation Market, By Product, 2017–2024 (USD Million)
Table 186 Vietnam: Immunoglobulins Market, By Type, 2017–2024 (USD Million)
Table 187 Vietnam: Coagulation Factor Concentrates Market, By Type, 2017–2024 (USD Million)
Table 188 Vietnam: Plasma Fractionation Market, By Application, 2017–2024 (USD Million)
Table 189 Vietnam: Plasma Fractionation Market, By End User, 2017–2024 (USD Million)
Table 190 Indonesia: Key Macroindicators for the Plasma Fractionation Market
Table 191 Indonesia: Plasma Fractionation Market, By Product, 2017–2024 (USD Million)
Table 192 Indonesia: Immunoglobulins Market, By Type, 2017–2024 (USD Million)
Table 193 Indonesia: Coagulation Factor Concentrates Market, By Type, 2017–2024 (USD Million)
Table 194 Indonesia: Plasma Fractionation Market, By Application, 2017–2024 (USD Million)
Table 195 Indonesia: Plasma Fractionation Market, By End User, 2017–2024 (USD Million)
Table 196 Malaysia: Number of Patients With Bleeding Disorders, 2012–2017
Table 197 Malaysia: Key Macroindicators for the Plasma Fractionation Market
Table 198 Malaysia: Plasma Fractionation Market, By Product, 2017–2024 (USD Million)
Table 199 Malaysia: Immunoglobulins Market, By Type, 2017–2024 (USD Million)
Table 200 Malaysia: Coagulation Factor Concentrates Market, By Type, 2017–2024 (USD Million)
Table 201 Malaysia: Plasma Fractionation Market, By Application, 2017–2024 (USD Million)
Table 202 Malaysia: Plasma Fractionation Market, By End User, 2017–2024 (USD Million)
Table 203 Rest of Asia Pacific: Plasma Fractionation Market, By Product, 2017–2024 (USD Million)
Table 204 Rest of Asia Pacific: Immunoglobulins Market, By Type, 2017–2024 (USD Million)
Table 205 Rest of Asia Pacific: Coagulation Factor Concentrates Market, By Type, 2017–2024 (USD Million)
Table 206 Rest of Asia Pacific: Plasma Fractionation Market, By Application, 2017–2024 (USD Million)
Table 207 Rest of Asia Pacific: Plasma Fractionation Market, By End User, 2017–2024 (USD Million)
Table 208 Brazil: Key Macroindicators for the Plasma Fractionation Market
Table 209 Mexico: Key Macroindicators for the Plasma Fractionation Market
Table 210 Latin America: Plasma Fractionation Market, By Product, 2017–2024 (USD Million)
Table 211 Latin America: Immunoglobulins Market, By Type, 2017–2024 (USD Million)
Table 212 Latin America: Coagulation Factor Concentrates Market, By Type, 2017–2024 (USD Million)
Table 213 Latin America: Plasma Fractionation Market, By Application, 2017–2024 (USD Million)
Table 214 Latin America: Plasma Fractionation Market, By End User, 2017–2024 (USD Million)
Table 215 Hemophilia Patients in the Middle East and Africa, 2012–2017
Table 216 Per Capita Consumption of Factor IX and VIII (Iu/Total Population) in South Africa, Saudi Arabia, and Iraq, 2012–2017
Table 217 Middle East & Africa: Plasma Fractionation Market, By Country, 2017–2024 (USD Million)
Table 218 Middle East & Africa: Plasma Fractionation Market, By Product, 2017–2024 (USD Million)
Table 219 Middle East & Africa: Immunoglobulins Market, By Type, 2017–2024 (USD Million)
Table 220 Middle East & Africa: Coagulation Factor Concentrates Market, By Type, 2017–2024 (USD Million)
Table 221 Middle East & Africa: Plasma Fractionation Market, By Application, 2017–2024 (USD Million)
Table 222 Middle East & Africa: Plasma Fractionation Market, By End User, 2017–2024 (USD Million)
Table 223 Turkey: Demographic Indicators
Table 224 Turkey: Reported Cases of Blood Disorders, 2012 vs 2014
Table 225 Turkey: Key Macroindicators for the Plasma Fractionation Market
Table 226 Turkey: Plasma Fractionation Market, By Product, 2017–2024 (USD Million)
Table 227 Turkey: Immunoglobulins Market, By Type, 2017–2024 (USD Million)
Table 228 Turkey: Coagulation Factor Concentrates Market, By Type, 2017–2024 (USD Million)
Table 229 Turkey: Plasma Fractionation Market, By Application, 2017–2024 (USD Million)
Table 230 Turkey: Plasma Fractionation Market, By End User, 2017–2024 (USD Million)
Table 231 Estimated Incidence and Prevalence of Cid, Scid, and Mhc Ii Deficiency in Children in Saudi Arabia
Table 232 Per Capita Consumption of Intravenous Immunoglobulin (IVIG) and Albumin (2015/2016)
Table 233 Saudi Arabia: Blood Disorder Cases, By Type, 2014 vs 2016
Table 234 Saudi Arabia: Key Macroindicators for the Plasma Fractionation Market
Table 235 Saudi Arabia: Plasma Fractionation Market, By Product, 2017–2024 (USD Million)
Table 236 Saudi Arabia: Immunoglobulins Market, By Type, 2017–2024 (USD Million)
Table 237 Saudi Arabia: Coagulation Factor Concentrates Market, By Type, 2017–2024 (USD Million)
Table 238 Saudi Arabia: Plasma Fractionation Market, By Application, 2017–2024 (USD Million)
Table 239 Saudi Arabia: Plasma Fractionation Market, By End User, 2017–2024 (USD Million)
Table 240 Egypt: Blood Disorder Cases, By Type, 2014–2017
Table 241 Egypt: Key Macroindicators for the Plasma Fractionation Market
Table 242 Egypt: Plasma Fractionation Market, By Product, 2017–2024 (USD Million)
Table 243 Egypt: Immunoglobulins Market, By Type, 2017–2024 (USD Million)
Table 244 Egypt: Coagulation Factor Concentrates Market, By Type, 2017–2024 (USD Million)
Table 245 Egypt: Plasma Fractionation Market, By Application, 2017–2024 (USD Million)
Table 246 Egypt: Plasma Fractionation Market, By End User, 2017–2024 (USD Million)
Table 247 UAE: Growth in the Number of Blood Donors
Table 248 UAE: Key Macroindicators for the Plasma Fractionation Market
Table 249 UAE: Plasma Fractionation Market, By Product, 2017–2024 (USD Million)
Table 250 UAE: Immunoglobulins Market, By Type, 2017–2024 (USD Million)
Table 251 UAE: Coagulation Factor Concentrates Market, By Type, 2017–2024 (USD Million)
Table 252 UAE: Plasma Fractionation Market, By Application, 2017–2024 (USD Million)
Table 253 UAE: Plasma Fractionation Market, By End User, 2017–2024 (USD Million)
Table 254 Hemophilia Patients in the Rest of Middle East and Africa, 2012 vs 2017
Table 255 Per Capita Consumption of Factor IX and VIII in South Africa and Qatar (Iu/Total Population), 2013 vs 2017
Table 256 RoMEA: Plasma Fractionation Market, By Product, 2017–2024 (USD Million)
Table 257 RoMEA: Immunoglobulins Market, By Type, 2017–2024 (USD Million)
Table 258 RoMEA: Coagulation Factor Concentrates Market, By Type, 2017–2024 (USD Million)
Table 259 RoMEA: Plasma Fractionation Market, By Application, 2017–2024 (USD Million)
Table 260 RoMEA: Plasma Fractionation Market, By End User, 2017–2024 (USD Million)
Table 261 Growth Strategy Matrix
Table 262 Product Launches/Approvals, January 2016 to April 2019
Table 263 Expansions, January 2016 to April 2019
Table 264 Acquisitions, January 2016 to April 2019
Table 265 Agreements, Collaborations, Joint Ventures, and Partnerships, January 2016 to April 2019

List of Figures (52 Figures)
Figure 1 Research Design
Figure 2 Supply Side: Breakdown of Primary Interviews: By Company Type, Designation, and Region
Figure 3 Demand Side: Breakdown of Primary Interviews: By End User, Designation, and Region
Figure 4 Data Triangulation Methodology
Figure 5 Immunoglobulins Segment to Dominate the Plasma Fractionation Market, By Product, From 2019 to 2024
Figure 6 Neurology Segment to Register the Highest Growth During the Forecast Period
Figure 7 Plasma Fractionation Market, By End User, 2019 vs 2024 (USD Million)
Figure 8 Geographic Snapshot: Plasma Fractionation Market in 2018
Figure 9 Growing Use of Immunoglobulins in Various Therapeutic Areas is the Major Factor Driving Market Growth
Figure 10 The US Accounted for the Largest Share of the Plasma Fractionation Market in 2018
Figure 11 Asia Pacific to Register the Highest CAGR During the Forecast Period
Figure 12 Developing Countries to Register Higher Growth During the Forecast Period
Figure 13 Global Percentage of Deaths From Respiratory Diseases, 2008 to 2030
Figure 14 Source Plasma Collection in the US, 2004–2017
Figure 15 Plasma Collection Centers in the US and Europe, 2007–2016
Figure 16 Number of Hemophilia A and Hemophilia B Patients Worldwide, 2012–2017
Figure 17 Increasing Consolidation and Rising Adoption of SCIG are the Leading Industry Trends
Figure 18 Plasma Fractionation Market in China vs US, 2017–2024
Figure 19 Porter’s Five Forces Analysis
Figure 20 Immunoglobulin Segment Will Continue to Dominate the Plasma Fractionation Market From 2019 to 2024
Figure 21 Prevalence of Bleeding Disorders, By Country, 2017
Figure 22 Mean Per Capita Usage of Factor VIII (2016 vs 2017)
Figure 23 Mean Per Capita Usage of Factor IX (2016 vs 2017)
Figure 24 Neurology Segment Will Continue to Dominate the Plasma Fractionation Market From 2019 to 2024
Figure 25 Number of Hemophilia Patients in Major Countries, 2016 vs 2017
Figure 26 Hospitals & Clinics to Register the Highest CAGR During the Forecast Period
Figure 27 North America to Dominate the Market During the Forecast Period
Figure 28 Plasma Fractionation Market: Geographic Growth Opportunities
Figure 29 North America: Plasma Fractionation Market Snapshot
Figure 30 Plasma Collection Volume in the US, 2004–2017
Figure 31 Plasma Collection Centers in the US, 2005–2017
Figure 32 Europe: Plasma Fractionation Market Snapshot
Figure 33 Hemophilia A & B Patients in Germany, 2013–2016
Figure 34 APAC: Plasma Fractionation Market Snapshot
Figure 35 Fresh Blood Expenditure in Australia, 2008–2017 (USD Million)
Figure 36 Mean Per Capita Use of Factor VIII and IX in Vietnam, 2014–2017 (Iu/Population)
Figure 37 Patient Population Suffering From Bleeding Disorders in Vietnam, 2014–2017
Figure 38 Blood Donation in Indonesia, 2011–2015 (Million Units)
Figure 39 Key Strategies Adopted By Players (January 2016 to April 2019)
Figure 40 Plasma Fractionation Market Share Analysis, By Key Player, 2018
Figure 41 Competitive Leadership Mapping
Figure 42 Csl: Company Snapshot (2018)
Figure 43 Grifols: Company Snapshot (2017)
Figure 44 Shire: Company Snapshot (2017)
Figure 45 Octapharma: Company Snapshot (2018)
Figure 46 Kedrion: Company Snapshot (2017)
Figure 47 LFB: Company Snapshot (2016)
Figure 48 Biotest: Company Snapshot (2017)
Figure 49 Sanquin: Company Snapshot (2017)
Figure 50 China Biologic Products: Company Snapshot (2017)
Figure 51 Japan Blood Products Organization: Company Snapshot (2016)
Figure 52 GC Pharma: Company Snapshot (2017)

Note: Product cover images may vary from those shown
3 of 6

Loading
LOADING...

4 of 6
5 of 6
  • Bio Products Laboratory (BPL)
  • Biotest
  • CSL
  • China Biologic Products
  • GC Pharma (Green Cross Corporation)
  • Grifols
  • Japan Blood Products Organization
  • Kedrion
  • LFB
  • Octapharma
  • Sanquin
  • Shanghai RAAS Blood Products
  • Shire
Note: Product cover images may vary from those shown
6 of 6
Note: Product cover images may vary from those shown
Order Online - visit: https://www.researchandmarkets.com/reports/4760748
Adroll
adroll